Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.

The original vision of the field of gynecologic oncology was to establish a multidisciplinary approach to the management of patients with gynecologic cancers. Fifty years later, scientific advances have markedly changed the overall practice of gynecologic oncology, but the profession continues to struggle to define its value-financial and otherwise. These issues were examined in full at the Society of Gynecologic Oncology (SGO) Future of the Profession Summit and the purpose of this document is to summarize the discussion, share the group's perceived strengths, weaknesses, opportunities, and threats (SWOT) for gynecologic oncologists, further educate members and others within the patient care team about the unique role of gynecologic oncologists, and plan future steps in the short- and long- term to preserve the subspecialty's critical mission of providing comprehensive, longitudinal care for people with gynecologic cancers.

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Huh reports personal fees from AstraZeneca, Roche, SeaGen and Inovio outside the submitted work. Dr. Hardesty reports personal fees from Immunogen, Axiom, GSK, Takeda, AZ-Mereck, and Intuitive outside the submitted work. Dr. Prendergast reports personal fees from Heron Therapeutics and AstraZeneca outside the submitted work. Dr. Rimel reports being an Advisory Board Participant for GSK, Merck, and Immunogen and a consultant for Deep 6AI. Dr. Shahin reports grants and personal fees from GSK, AstraZeneca, and Merck, personal fees from Eisai, Immunogen, and GenMab during the conduct of the study. All other authors have nothing to disclose.